Source: davit kirakosyan
Neutral Rating Reiterated for Biohaven Following Disappointing Clinical Results
H.C. Wainwright, a leading financial services firm, has reiterated its Neutral rating and $11 price target on Biohaven Pharmaceutical Holding Co. (NYSE: BHVN). This decision came in the wake of disappointing clinical results for Biohaven’s drug candidate, BHV-7000, which is targeted at treating major depressive disorder (MDD).
Unsurprising Failure in MDD
The financial services firm expressed that it was not taken aback by the failure of BHV-7000 in treating MDD. This sentiment aligns with the general investor sentiment, which had primarily been focused on the upcoming readout for focal onset seizure, another area of Biohaven’s research. Despite the underwhelming performance of BHV-7000, some investors had maintained optimism, hoping that the MDD data might provide a positive catalyst ahead of the focal onset seizure (FOS) results.
However, the trial outcome, far from providing the hoped-for boost, instead reinforced a cautious stance among investors and analysts. This is a clear reminder of the inherent risks involved in pharmaceutical research and development, where a drug candidate’s success is never guaranteed until it has passed through rigorous clinical trials and received regulatory approval.
Failure to Meet Primary and Secondary Endpoints
The clinical study of Biohaven’s BHV-7000 failed to meet its primary endpoint. The primary goal was an improvement in the Montgomery-Asberg Depression Rating Scale (MADRS) scores over a period of six weeks when compared to a placebo. The MADRS is a ten-item diagnostic questionnaire used by psychiatrists to measure the severity of depressive episodes in patients with mood disorders.
In addition to falling short on the primary endpoint, the study also missed secondary endpoints including the Clinical Global Impression-Severity scale (CGI-S) and the Snaith-Hamilton Pleasure Scale (SHAPS). These are additional tools used in the clinical evaluation of depression severity and the presence of anhedonia (the inability to feel pleasure), respectively.
While Biohaven had plans to conduct additional subgroup analyses, H.C. Wainwright emphasized that these would be exploratory only. No further trials are planned for the program, signifying the firm’s decision to draw a line under this particular avenue of research.
Shifting Priorities for Biohaven
As a consequence of the disappointing results, Biohaven intends to redirect its focus toward priority areas in 2026. These include immunology, obesity, and epilepsy. This strategic shift underscores the adaptive nature of pharmaceutical companies and their ability to pivot based on clinical trial outcomes.
The analyst at H.C. Wainwright added that the disappointing BHV-7000 results did not materially affect expectations for Xenon Pharmaceuticals’ azetukalner Phase 3 MDD program. This suggests that the broader landscape of MDD treatment research may remain unaffected by Biohaven’s setback.
To conclude, despite the failure of BHV-7000 in MDD, the Neutral rating on Biohaven was reaffirmed by H.C. Wainwright. The firm’s price target remains at $11, underlining the belief that Biohaven, while experiencing a setback, still holds potential in its other areas of focus including immunology, obesity, and epilepsy.